Advertisement

Neurocutaneous Syndromes

Chapter
  • 522 Downloads

Abstract

Neurocutaneous syndromes comprise diagnoses that affect the nervous system and skin on the basis of common embryologic origin from ectoderm. Abnormal cell proliferation and organization can manifest as tumor potential or vascular abnormalities in multiple locations; these can produce symptoms across the life span. An understanding of the natural history has guided recommendations to screen affected individuals and at-risk family members. With increasing research at a genetic and pathophysiologic level, there has been improved availability of treatment options not only for these specific conditions but others as well.

References

  1. 1.
    Morgan JE, Wolfort F. The early history of tuberous sclerosis. Arch Dermatol. 1979;115:1317–9.PubMedGoogle Scholar
  2. 2.
    Crino PB, Nathanson KL, Henske EP. The tuberous sclerosis complex. N Engl J Med. 2006;355:1345–56.PubMedGoogle Scholar
  3. 3.
    Sancak O. Tuberous sclerosis complex: mutations, Functions and phenotypes. PhD thesis, Erasmus University Rotterdam; 2005Google Scholar
  4. 4.
    Sancak O, Nellist M, Goedbloed M, Elfferich P, Wouters C, Maat-Kievit A, Zonnenberg B, Verhoef S, Halley D, Van Den Ouweland A. Mutational analysis of the TSC1 and TSC2 genes in a diagnostic setting: genotype–phenotype correlations and comparison of diagnostic DNA techniques in tuberous sclerosis complex. Eur J Hum Genet. 2005;13:731–41.PubMedGoogle Scholar
  5. 5.
    Roach ES, Gomez MR, Northrup H. Tuberous sclerosis complex consensus conference: revised clinical diagnostic criteria. J Child Neurol. 1998;13:624–8.PubMedGoogle Scholar
  6. 6.
    Northrup H, Krueger DA, Roberds S, Smith K, Sampson J, Korf B, Kwiatkowski DJ, Mowat D, Nellist M, Povey S, De Vries P, Byars A, Dunn D, Ess K, Hook D, Jansen A, King B, Sahin M, Whittemore V, Thiele E, Bebin EM, Chugani HT, Crino P, Curatolo P, Holmes G, Nabbout R, O’callaghan F, Wheless J, Wu J, Darling TN, Cowen EW, Gosnell E, Hebert A, Mlynarczyk G, Soltani K, Teng J, Wataya-Kaneda M, Witman PM, Kingswood C, Bissler J, Budde K, Hulbert J, Guay-Woodford L, Sauter M, Zonneberg B, Jóźwiak S, Bartels U, Berhouma M, Franz DN, Koenig MK, Roach ES, Roth J, Wang H, Weiner H, McCormack FX, Almoosa K, Brody A, Burger C, Cottin V, Finlay G, Glass J, Henske EP, Johnson S, Kotloff R, Lynch D, Moss J, Smith K, Rhu J, Da S, T A, Young LR, Knilans T, Hinton R, Prakash A, Romp R, Singh AD, Debroy A, Chen P-L, Sparagana S, Frost MD. Tuberous sclerosis complex diagnostic criteria update: recommendations of the 2012 international tuberous sclerosis complex consensus conference. Pediatr Neurol. 2013;49:243–54.PubMedPubMedCentralGoogle Scholar
  7. 7.
    Manning BD, Cantley LC. United at last: the tuberous sclerosis complex gene products connect the phosphoinositide 3-kinase/Akt pathway to mammalian target of rapamycin (mTOR) signalling. Biochem Soc Trans. 2003;31:573–8.PubMedGoogle Scholar
  8. 8.
    Tee AR, Fingar DC, Manning BD, Kwiatkowski DJ, Cantley LC, Blenis J. Tuberous sclerosis complex-1 and -2 gene products function together to inhibit mammalian target of rapamycin (mTOR)-mediated downstream signaling. Proc Natl Acad Sci U S A. 2002;99:13571–6.PubMedPubMedCentralGoogle Scholar
  9. 9.
    Franz DN, Belousova E, Sparagana S, Bebin EM, Frost M, Kuperman R, Witt O, Kohrman MH, Flamini JR, Wu JY, Curatolo P, De Vries PJ, Whittemore VH, Thiele EA, Ford JP, Shah G, Cauwel H, Lebwohl D, Sahmoud T. Jozwiak S. Efficacy and safety of everolimus for subependymal giant cell astrocytomas associated with tuberous sclerosis complex (EXIST-1): a multicentre, randomised, placebo-controlled phase 3 trial. The Lancet. 2013;381:125–32.Google Scholar
  10. 10.
    Bissler JJ, Kingswood JC, Radzikowska E, Zonnenberg BA, Frost M, Belousova E, Sauter M, Nonomura N, Brakemeier S, De Vries PJ, Whittemore VH, Chen D, Sahmoud T, Shah G, Lincy J, Lebwohl D, Budde K. Everolimus for angiomyolipoma associated with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis (EXIST-2): a multicentre, randomised, doubleblind, placebo-controlled trial. The Lancet. 2013;381:817–24.Google Scholar
  11. 11.
    Schwartz RA, Fernández G, Kotulska K, Jóźwiak S. Tuberous sclerosis complex: advances in diagnosis, genetics, and management. J Am Acad Dermatol. 2007;57:189–202.PubMedGoogle Scholar
  12. 12.
    Józwiak S, Schwartz RA, Janniger CK, Michałowicz R, Chmielik J. Skin lesions in children with tuberous sclerosis complex: their prevalence, natural course, and diagnostic significance. Int J Dermatol. 1998;37:911–7.PubMedGoogle Scholar
  13. 13.
    Liebman JJ, Nigro LC, Matthews MS. Koenen tumors in tuberous sclerosis: a review and clinical considerations for treatment. Ann Plast Surg. 2014;73:721–2.PubMedGoogle Scholar
  14. 14.
    Dimario FJ. Brain abnormalities in tuberous sclerosis complex. J Child Neurol. 2004;19:650–7.PubMedGoogle Scholar
  15. 15.
    Romanelli P, Verdecchia M, Rodas R, Seri S, Curatolo P. Epilepsy surgery for tuberous sclerosis. Pediatr Neurol. 2004;31:239–47.PubMedGoogle Scholar
  16. 16.
    De Vries PJ, Whittemore VH, Leclezio L, Byars AW, Dunn D, Ess KC, Hook D, King BH, Sahin M, Jansen A. Tuberous sclerosis associated neuropsychiatric disorders (TAND) and the TAND checklist. Pediatr Neurol. 2015;52:25–35.PubMedGoogle Scholar
  17. 17.
    Webb DW, Thomas RD, Osborne JP. Cardiac rhabdomyomas and their association with tuberous sclerosis. Arch Dis Child. 1993;68:367–70.PubMedPubMedCentralGoogle Scholar
  18. 18.
    Eijkemans MJC, van der Wal W, Reijnders LJ, Roes KCB, van Waalwijk van Doorn-Khosrovani SB, Pelletier C, Magestro M, Zonnenberg B. Long-term follow-up assessing renal angiomyolipoma treatment patterns, morbidity, and mortality: an observational study in tuberous sclerosis complex patients in the Netherlands. Am J Kidney Dis. 2015;66:638–45.PubMedGoogle Scholar
  19. 19.
    Krueger DA, Northrup H, Roberds S, Smith K, Sampson J, Korf B, Kwiatkowski DJ, Mowat D, Nellist M, Povey S, De Vries P, Byars A, Dunn D, Ess K, Hook D, Jansen A, King B, Sahin M, Whittemore V, Thiele E, Bebin EM, Chugani HT, Crino P, Curatolo P, Holmes G, Nabbout R, O’callaghan F, Wheless J, Wu J, Darling TN, Cowen EW, Gosnell E, Hebert A, Mlynarczyk G, Soltani K, Teng J, Wataya-Kaneda M, Witman PM, Kingswood C, Bissler J, Budde K, Hulbert J, Guay-Woodford L, Sauter M, Zonneberg B, Jóźwiak S, Bartels U, Berhouma M, Franz DN, Koenig MK, Roach ES, Roth J, Wang H, Weiner H, McCormack FX, Almoosa K, Brody A, Burger C, Cottin V, Finlay G, Glass J, Henske EP, Johnson S, Kotloff R, Lynch D, Moss J, Smith K, Rhu J, Da Silva AT, Young LR, Knilans T, Hinton R, Prakash A, Romp R, Singh AD, Debroy A, Chen P-L, Sparagana S, Frost MD. Tuberous sclerosis complex surveillance and management: recommendations of the 2012 international tuberous sclerosis complex consensus conference. Pediatr Neurol. 2013;49:255–65.PubMedPubMedCentralGoogle Scholar
  20. 20.
    Rasmussen SA, Friedman JM. NF1 gene and neurofibromatosis 1. Am J Epidemiol. 2000;151:33–40.PubMedGoogle Scholar
  21. 21.
    Gutmann DH, Aylsworth A, Carey JC, et al. The diagnostic evaluation and multidisciplinary management of neurofibromatosis 1 and neurofibromatosis 2. JAMA. 1997;278:51–7.PubMedGoogle Scholar
  22. 22.
    Millichap JG. MRI screening for optic gliomas in neurofibromatosis Type 1. Pediatr Neurol Briefs. 2015;29:72.PubMedPubMedCentralGoogle Scholar
  23. 23.
    Williams VC, Lucas J, Babcock MA, Gutmann DH, Korf B, Maria BL. Neurofibromatosis type 1 revisited. Pediatrics. 2008;123:124–33.Google Scholar
  24. 24.
    Rosser TL, Vezina G, Packer RJ. Cerebrovascular abnormalities in a population of children with neurofibromatosis type 1. Neurology. 2005;64:553–5.PubMedGoogle Scholar
  25. 25.
    Steen RG, Taylor JS, Langston JW, Glass JO, Brewer VR, Reddick WE, Mages R, Pivnick EK. Prospective evaluation of the brain in asymptomatic children with neurofibromatosis type 1: relationship of macrocephaly to T1 relaxation changes and structural brain abnormalities. Am J Neuroradiol. 2001;22:810–7.PubMedGoogle Scholar
  26. 26.
    Listernick R, Ferner RE, Liu GT, Gutmann DH. Optic pathway gliomas in neurofibromatosis-1: controversies and recommendations. Ann Neurol. 2007;61:189–98.PubMedGoogle Scholar
  27. 27.
    Evans D, Baser M, Mcgaughran J, Sharif S, Howard E, Moran A. Malignant peripheral nerve sheath tumours in neurofibromatosis 1. J Med Genet. 2002;39:311–4.PubMedPubMedCentralGoogle Scholar
  28. 28.
    Mautner V-F, Asuagbor FA, Dombi E, Fünsterer C, Kluwe L, Wenzel R, Widemann BC, Friedman JM. Assessment of benign tumor burden by whole-body MRI in patients with neurofibromatosis 1. Neuro-Oncology. 2008;10:593–8.PubMedPubMedCentralGoogle Scholar
  29. 29.
    Hagel C, Lindenau M, Lamszus K, Kluwe L, Stavrou D, Mautner V-F. Polyneuropathy in neurofibromatosis 2: clinical findings, molecular genetics and neuropathological alterations in sural nerve biopsy specimens. Acta Neuropathol. 2002;104:179–87.PubMedGoogle Scholar
  30. 30.
    Evans DGR, Huson SM, Donnai D, Neary W, Blair V, Newton V, Harris R. A clinical study of type 2 neurofibromatosis. QJM. 1992;84:603–18.PubMedGoogle Scholar
  31. 31.
    Xiao G-H, Chernoff J, Testa JR. NF2: the wizardry of merlin. Genes Chromosom Cancer. 2003;38:389–99.PubMedGoogle Scholar
  32. 32.
    Plotkin SR, Stemmer-Rachamimov AO, Barker FGI, Halpin C, Padera TP, Tyrrell A, Sorensen AG, Jain RK, Di Tomaso E. Hearing improvement after bevacizumab in patients with neurofibromatosis type 2. N Engl J Med. 2009;361:358–67.PubMedPubMedCentralGoogle Scholar
  33. 33.
    Comi A. Current therapeutic options in Sturge-Weber syndrome. Semin Pediatr Neurol. 2015;22:295–301.PubMedPubMedCentralGoogle Scholar
  34. 34.
    Pinto AL, Chen L, Friedman R, Grant PE, Poduri A, Takeoka M, Prabhu SP, Sahin M. Sturge-Weber syndrome: brain magnetic resonance imaging and neuropathology findings. Pediatr Neurol. 2016;58:25–30.PubMedGoogle Scholar
  35. 35.
    Aylett SE, Neville BGR, Cross JH, Boyd S, Chong WK, Kirkham FJ. Sturge–Weber syndrome: cerebral haemodynamics during seizure activity. Dev Med Child Neurol. 1999;41:480–5.PubMedGoogle Scholar
  36. 36.
    Lance EI, Sreenivasan AK, Zabel TA, Kossoff EH, Comi AM. Aspirin use in Sturge-Weber syndrome: side effects and clinical outcomes. J Child Neurol. 2013;28:213–8.PubMedGoogle Scholar
  37. 37.
    Shirley MD, Tang H, Gallione CJ, Baugher JD, Frelin LP, Cohen B, North PE, Marchuk DA, Comi AM, Pevsner J. Sturge–Weber syndrome and port-wine stains caused by somatic mutation in GNAQ. N Engl J Med. 2013;368:1971–9.PubMedPubMedCentralGoogle Scholar
  38. 38.
    Lonser RR, Glenn GM, Walther M, Chew EY, Libutti SK, Linehan WM, Oldfield EH. von Hippel-Lindau disease. Lancet. 2003;361:2059–67.PubMedGoogle Scholar
  39. 39.
    Walther MM, Choyke PL, Glenn G, Lyne JC, Rayford W, Venzon D, Linehan WM. Renal cancer in families with hereditary renal cancer: prospective analysis of a tumor size threshold for renal parenchymal sparing surgery. J Urol. 1999;161:1475–9.PubMedGoogle Scholar
  40. 40.
    Wong WT, Agrón E, Coleman HR, Tran T, Reed GF, Csaky K, Chew EY. Clinical characterization of retinal capillary hemangioblastomas in a large population of patients with von Hippel–Lindau disease. Ophthalmology. 2008;115:181–8.PubMedGoogle Scholar
  41. 41.
    Kim HJ, Butman JA, Brewer C, Zalewski C, Vortmeyer AO, Glenn G, Oldfield EH, Lonser RR. Tumors of the endolymphatic sac in patients with von Hippel–Lindau disease: implications for their natural history, diagnosis, and treatment. J Neurosurg. 2005;102:503–12.PubMedGoogle Scholar
  42. 42.
    Chen F, Kishida T, Yao M, Hustad T, Glavac D, Dean M, Gnarra JR, Orcutt ML, Duh FM, Glenn G, Green J, Hsia YE, Lamiell J, Li H, Wei MH, Schmidt L, Tory K, Kuzmin I, Stackhouse T, Latif F, Linehan WM, Lerman M, Zbar B. Germline mutations in the von Hippel–Lindau disease tumor suppressor gene: correlations with phenotype. Hum Mutat. 1995;5:66–75.PubMedGoogle Scholar
  43. 43.
    Shovlin CLC. Diagnostic criteria for hereditary hemorrhagic telangiectasia (Rendu-Osler-Weber syndrome). Am J Med Genet. 2000;91:66–7.PubMedPubMedCentralGoogle Scholar
  44. 44.
    Garcia-Tsao G. Liver involvement in hereditary hemorrhagic telangiectasia (HHT). J Hepatol. 2007;46:499–507.PubMedGoogle Scholar
  45. 45.
    Goussous T, Haynes A, Najarian K, Daccarett M, David S. Hereditary hemorrhagic telangiectasia presenting as high output cardiac failure during pregnancy. Cardiol Res Pract. 2009;2009:437237.PubMedPubMedCentralGoogle Scholar
  46. 46.
    Román GG. Neurological manifestations of hereditary hemorrhagic telangiectasia (Rendu-Osler-Weber disease): report of 2 cases and review of the literature. Ann Neurol. 1978;4:130–44.PubMedGoogle Scholar
  47. 47.
    Fulbright RK, Chaloupka JC, Putman CM, Sze GK, Merriam MM, Lee GK, Fayad PB, Awad IA, White RI. MR of hereditary hemorrhagic telangiectasia: prevalence and spectrum of cerebrovascular malformations. Am J Neuroradiol. 1998;19:477–84.PubMedGoogle Scholar
  48. 48.
    Elphick A, Shovlin CL. Relationships between epistaxis, migraines, and triggers in hereditary hemorrhagic telangiectasia. Laryngoscope. 2014;124:1521–8.PubMedGoogle Scholar
  49. 49.
    Faughnan ME, Palda VA, Garcia-Tsao G, Geisthoff UW, McDonald J, Proctor DD, Spears J, Brown DH, Buscarini E, Chesnutt MS, Cottin V, Ganguly A, Gossage JR, Guttmacher AE, Hyland RH, Kennedy SJ, Korzenik J, Mager JJ, Ozanne AP, Piccirillo JF, Picus D, Plauchu H, Porteous MEM, Pyeritz RE, Ross DA, Sabba C, Swanson K, Terry P, Wallace MC, Westermann CJJ, White RI, Young LH, Zarrabeitia R. International guidelines for the diagnosis and management of hereditary haemorrhagic telangiectasia. J Med Genet. 2011;48:73–87.PubMedPubMedCentralGoogle Scholar
  50. 50.
    Letteboer TGW, Mager H-J, Snijder RJ, Lindhout D, Ploos Van Amstel H-K, Zanen P, Westermann KJJ. Genotype–phenotype relationship for localization and age distribution of telangiectases in hereditary hemorrhagic telangiectasia. Am J Med Genet A. 2008;146A:2733–9.PubMedGoogle Scholar
  51. 51.
    Landy SJ, Donnai D. Incontinentia pigmenti (Bloch-Sulzberger syndrome). J Med Genet. 1993;30:53–9.PubMedPubMedCentralGoogle Scholar
  52. 52.
    Wiklund DA, Weston WL. Incontinentia pigmenti: a four-generation study. Arch Dermatol. 1980;116:701–3.PubMedGoogle Scholar
  53. 53.
    Phan TA, Wargon O, Turner AM. Incontinentia pigmenti case series: clinical spectrum of incontinentia pigmenti in 53 female patients and their relatives. Clin Exp Dermatol. 2005;30:474–80.PubMedGoogle Scholar
  54. 54.
    François J. Incontinentia pigmenti (Bloch-Sulzberger syndrome) and retinal changes. Br J Ophthalmol. 1984;68:19–25.PubMedPubMedCentralGoogle Scholar
  55. 55.
    Meuwissen MEC, Mancini GMS. Neurological findings in incontinentia pigmenti; a review. Eur J Med Genet. 2012;55:323–31.PubMedGoogle Scholar
  56. 56.
    Smahi A, Courtois G, Vabres P, Yamaoka S, Heuertz S, Munnich A, IsraËL A, Heiss NS, Klauck SM, Kioschis P, Wiemann S, Poustka A, Esposito T, Bardaro T, Gianfrancesco F, Ciccodicola A, D’urso M, Woffendin H, Jakins T, Donnai D, Stewart H, Kenwrick SJ, Aradhya S, Yamagata T, Levy M, Lewis RA, Nelson DL. Genomic rearrangement in NEMO impairs NF-[kappa]B activation and is a cause of incontinentia pigmenti. Nature. 2000;405:466–72.PubMedGoogle Scholar
  57. 57.
    Sybert VP. Hypomelanosis of Ito. Pediatr Dermatol. 1990;7:74–6.PubMedGoogle Scholar
  58. 58.
    Ruiz-Maldonado R, Toussaint S, Tamayo L, Laterza A, Del Castillo V. Hypomelanosis of Ito: diagnostic criteria and report of 41 cases. Pediatr Dermatol. 1992;9:1–10.PubMedGoogle Scholar
  59. 59.
    Ruggieri M, Pavone L. Topical review: hypomelanosis of Ito: clinical syndrome or just phenotype? J Child Neurol. 2000;15:635–44.PubMedGoogle Scholar
  60. 60.
    Pascual-Castroviejo I, Roche C, Martinez-Bermejo A, Arcas J, Lopez-Martin V, Tendero A, Esquiroz JLH, Pascual-Pascual S-I. Hypomelanosis of ITO. A study of 76 infantile cases. Brain Dev. 1998;20:36–43.PubMedGoogle Scholar
  61. 61.
    Donnai D, Read AP, Mckeown C, Andrews T. Hypomelanosis of Ito: a manifestation of mosaicism or chimerism. J Med Genet. 1988;25:809–18.PubMedPubMedCentralGoogle Scholar
  62. 62.
    Boder E, Sedgwick RP. Ataxia-telangiectasia. A familial syndrome of progressive cerebellar ataxia, oculocutaneous telangiectasia and frequent pulmonary infection. Pediatrics. 1958;21:526–54.PubMedGoogle Scholar
  63. 63.
    Crawford TO. Ataxia telangiectasia. Semin Pediatr Neurol. 1998;5:287–94.PubMedGoogle Scholar
  64. 64.
    Tavani F, Zimmerman RA, Berry GT, Sullivan K, Gatti R, Bingham P. Ataxia-telangiectasia: the pattern of cerebellar atrophy on MRI. Neuroradiology. 2003;45:315–9.PubMedGoogle Scholar
  65. 65.
    Farr AK, Shalev B, Crawford TO, Lederman HM, Winkelstein JA, Repka MX. Ocular manifestations of ataxia-telangiectasia. Am J Ophthalmol. 2002;134:891–6.PubMedGoogle Scholar
  66. 66.
    Greenberger S, Berkun Y, Ben-Zeev B, Levi YB, Barziliai A, Nissenkorn A. Dermatologic manifestations of ataxia-telangiectasia syndrome. J Am Acad Dermatol. 2013;68:932–6.PubMedGoogle Scholar
  67. 67.
    Nowak-Wegrzyn A, Crawford TO, Winkelstein JA, Carson KA, Lederman HM. Immunodeficiency and infections in ataxia-telangiectasia. J Pediatr. 2004;144:505–11.PubMedGoogle Scholar
  68. 68.
    Micol R, Ben Slama L, Suarez F, Le Mignot L, Beauté J, Mahlaoui N, Dubois D’enghien C, Laugé A, Hall J, Couturier J, Vallée L, Delobel B, Rivier F, Nguyen K, Billette De Villemeur T, Stephan J-L, Bordigoni P, Bertrand Y, Aladjidi N, Pedespan J-M, Thomas C, Pellier I, Koenig M, Hermine O, Picard C, Moshous D, Neven B, Lanternier F, Blanche S, Tardieu M, Debré M, Fischer A, Stoppa-Lyonnet D. Morbidity and mortality from ataxia-telangiectasia are associated with ATM genotype. J Aller Clin Immunol. 2011;128:382–389.e1.Google Scholar
  69. 69.
    Mavrou A, Tsangaris GTH, Roma E, Kolialexi A. The ATM gene and ataxia telangiectasia. Anticancer Res. 2008;28:401–5.PubMedGoogle Scholar
  70. 70.
    Cabana MD, Crawford TO, Winkelstein JA, Christensen JR, Lederman HM. Consequences of the delayed diagnosis of ataxia-telangiectasia. Pediatrics. 1998;102:98–100.PubMedGoogle Scholar
  71. 71.
    Ramaswamy V, Delaney H, Haque S, Marghoob A, Khakoo Y. Spectrum of central nervous system abnormalities in neurocutaneous melanocytosis. Dev Med Child Neurol. 2012;54:563–8.PubMedGoogle Scholar
  72. 72.
    Agero ALC, Benvenuto-Andrade C, Dusza SW, Halpern AC, Marghoob AA. Asymptomatic neurocutaneous melanocytosis in patients with large congenital melanocytic nevi: a study of cases from an Internet-based registry. J Am Acad Dermatol. 2005;53:959–65.PubMedGoogle Scholar
  73. 73.
    Dedavid M, Orlow SJ, Provost N, Marghoob AA, Rao BK, Wasti Q, Huang CL, Kopf AW, Bart RS. Neurocutaneous melanosis: clinical features of large congenital melanocytic nevi in patients with manifest central nervous system melanosis. J Am Acad Dermatol. 1996;35:529–38.PubMedGoogle Scholar
  74. 74.
    Kadonaga JN, Frieden IJ. Neurocutaneous melanosis: definition and review of the literature. J Am Acad Dermatol. 1991;24:747–55.PubMedGoogle Scholar
  75. 75.
    Lovett A, Maari C, Decarie J-C, Marcoux D, Mccuaig C, Hatami A, Savard P, Powell J. Large congenital melanocytic nevi and neurocutaneous melanocytosis: one pediatric center’s experience. J Am Acad Dermatol. 2009;61:766–74.PubMedGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2020

Authors and Affiliations

  1. 1.Department of Pediatrics, Section of Child NeurologyThe Ohio State University College of MedicineColumbusUSA

Personalised recommendations